Drug Development

Oct 24, 2017
By Pharmaceutical Technology Editors
The CDMO is investing £6 million into a new facility at its United Kingdom site to expand its milling, micronization, and solid form capabilities.
Oct 24, 2017
By Pharmaceutical Technology Editors
Innovator companies are exploring new avenues to keep generic drugs at bay, says CPhI expert, but competition authorities and drug regulators will play a key role in preventing such abusive anti-competitive practices.
Oct 23, 2017
By Pharmaceutical Technology Editors
The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.
Oct 20, 2017
By Pharmaceutical Technology Editors
The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.
Oct 20, 2017
By Pharmaceutical Technology Editors
This approval marks the second gene therapy to be approved by FDA and the first to be approved for certain types of non-Hodgkin lymphoma.
Oct 17, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
CordenPharma will expand development capacity for small molecules, peptides, and carbohydrates at its Liestal, Switzerland site
Oct 16, 2017
By Pharmaceutical Technology Editors
Dow’s portfolio of solutions for pharmaceutical applications now includes products from Dow Corning’s silicone technology platform.
Oct 16, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
Piramal is investing $55 million into the expansion of its API manufacturing capabilities and capacities across sites in North America and Asia.
Oct 16, 2017
By Pharmaceutical Technology Editors
The company announced plans to expand its viral vector process development facilities in the United States and its cleanroom facilities in the Netherlands for vector-based products.
Oct 16, 2017
By Pharmaceutical Technology Editors
The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.
native1_300x100
lorem ipsum